NCT06794710Not yet recruiting
Early Identification and Treatment of Rare Cardiomyopathy Cohorts
Early Identification and Treatment of Rare Myocardium by Multimodal Imaging (EARLY-MYO-RARE)
Source: ClinicalTrials.gov · Last updated 27 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to further develop an imaging-guided cohort of rare cardiomyopathies based on the existing database. The investigators will standardize the construction of a cohort that integrates a clinical data repository, serum biobank, myocardial tissue bank, and imaging database. In the current cohort, the investigators will systematically screen for biomarkers indicative of pathological changes in challenging cardiomyopathies. Multidimensional data will be integrated to establish and optimize a heart failure risk assessment model, which will then be validated in a prospective cohort. The effectiveness of the model in assessing different risk groups will be evaluated, with the goal of achieving precise prevention of heart failure from the source.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 30 Dec 2024
- Start date
- 1 Feb 2025
- Primary completion date
- 30 May 2027
- Lead sponsor
- RenJi Hospital
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT06794710
What you commit to
- Study type: Interventional
- Planned participants: 300
- From 1 Feb 2025 to the primary completion date, 30 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of cardiovascular disease such as confirmed coronary artery disease, valvular disease, cardiomyopathy, congenital heart disease, and heart failure.
Lab values
- Presence of acute/chronic renal impairment (GFR \<50/ml/min/1.73m2).
Other
- Presence of contraindications to CMR.
Who the study is looking for
- Age 18-75 years old.
- Patients preliminarily diagnosed with heart failure and scheduled to receive drug therapy after being evaluated by cardiology departments.
- No history of structural heart disease, and the Framingham score \<5 (for patients with the Framingham score ≥5, coronary artery disease will be excluded by coronary angiography/coronary CT/exercise platelet).
- Creatinine clearance ≥50ml/min (Cockcroft-Gault formula).
- LVEF ≥50% assessed by Echocardiography.
- QT interval \< 470 ms.
- Providing written informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| RenJi Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.